What is Akebia Therapeutics, Inc.'s (AKBA) StockRank?

MoatMap's StockRank for Akebia Therapeutics, Inc. (AKBA) is 18/100, with a Strong Sell signal. This is a composite score combining Quality (48), Value (42), and Momentum (13) factor ranks across MoatMap's 20,000+ stock universe.

Does Akebia Therapeutics, Inc. have an economic moat?

Akebia Therapeutics, Inc. (AKBA) has a Quality factor score of 48/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Akebia Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Akebia Therapeutics, Inc. (AKBA) is Strong Sell, based on a StockRank of 18/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Akebia Therapeutics, Inc. in?

Akebia Therapeutics, Inc. (AKBA) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

AKBA

STRONG SELLREMOVE

Akebia Therapeutics, Inc. · Healthcare · United States · $299M · Avg Vol: $6M/d

StockRank

P/E (TTM)

—

ROE

-79.0%

D/E

7.2x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Speculative biopharmaceutical company with high cash burn and a weak quantitative profile, failing our quality compounder test.

COMPANY DESCRIPTION

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. The company's lead product, Vafseo (vadadustat), is an oral HIF-PH inhibitor designed to treat anemia associated with chronic kidney disease. Akebia's competitive position is anchored by its specialized renal pipeline and established commercial infrastructure in the nephrology market.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	292.5M	194.6M	160.2M	236.2M	-6.9%
EPS	-0.51	-0.28	-0.33	-0.02	—
Shares	184.1M	194.6M	224.8M	265.4M	+44.1%
Debt	99.8M	48.1M	47.6M	51.8M	-19.6%
Equity	5.2M	-30.6M	-49.2M	32.6M	84.1%
Op CF	-73.2M	-23.4M	-40.7M	68.0M	—
Inv CF	-0.1M	0	-33,000	-7.9M	—
Fin CF	14.6M	-25.2M	49.7M	72.9M	—

PRICE (1Y)-10.2%

SMA 50SMA 200

$1.06

RSI (14)

62.3

52W High

$4.08

From 52W High

0.3%

SCORE BREAKDOWN

Quality

ROIC

9.6%72.3

ROE

-79.0%10.6

GP/Assets

50.6%86.7

Op. Margin

-2.8%33.1

FCF/Assets

17.5%94.8

Piotroski

666.7

Int. Cover

0.8x38.0

D/E Ratio

7.22x1.3

Current Ratio

1.40x22.2

Value

P/E (TTM)

—N/A

EV/EBITDA

26.5x21.4

P/FCF

4.5x95.2

P/B

10.6x10.7

P/S

1.3x79.3

Div Yield

—N/A

Momentum

52W High %

26%4.3

RS 6M

-44%26.6

SMA 50/200

0.69x5.2

EPS Rev 4W

0.0%49.2

EPS Rev 12W

—N/A

EPS Improve

-138%2.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$299M

P/E (Forward)

-5.7x

Gross Margin

81.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AKBA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
AKBA	Akebia Therapeutics, Inc.(you)	$299M	18	STRONG SELL
DERM	Journey Medical Corporation	$180M	19	STRONG SELL
ORGO	Organogenesis Holdings Inc.	$309M	31	SELL
CL.CN	Cresco Labs Inc.	$293M	31	SELL
LFCR	Lifecore Biomedical, Inc.	$207M	10	STRONG SELL
TKNO	Alpha Teknova, Inc.	$272M	32	SELL
EOLS	Evolus, Inc.	$432M	32	SELL
AQST	Aquestive Therapeutics, Inc.	$609M	11	STRONG SELL
VREO.CN	Vireo Growth Inc.	$532M	28	SELL
JUSH.CN	Jushi Holdings Inc.	$93M	25	SELL

Peer medians: ROE -23.1% · P/E 25.2x · Gross margin 44.3%

Akebia Therapeutics, Inc. (AKBA) — Stock Score Summary

Akebia Therapeutics, Inc. (AKBA) has a MoatMap StockRank of 18/100 based on Quality (48/100), Value (42/100), and Momentum (13/100) factor scores. The current signal is STRONG SELL. Speculative biopharmaceutical company with high cash burn and a weak quantitative profile, failing our quality compounder test.

Key Financial Metrics

Price	$1.06
Market Cap	$299M
P/E (Forward)	-5.71
Price/Book	10.64
Return on Equity	-79.0%
Return on Invested Capital	9.6%
Debt/Equity	721.55
Gross Margin	81.9%
Operating Margin	-2.8%
Revenue Growth	-6.6%
Free Cash Flow	$66M

Akebia Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Akebia Therapeutics, Inc.’s (AKBA) StockRank?: MoatMap’s StockRank for Akebia Therapeutics, Inc. (AKBA) is 18/100, with a Strong Sell signal. It is a composite of Quality (48), Value (42), and Momentum (13) factor ranks across MoatMap’s 20,000+ stock universe.
Does Akebia Therapeutics, Inc. have an economic moat?: Akebia Therapeutics, Inc. (AKBA) has a Quality factor score of 48/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Akebia Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Akebia Therapeutics, Inc. (AKBA) is Strong Sell, based on a StockRank of 18/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Akebia Therapeutics, Inc. in?: Akebia Therapeutics, Inc. (AKBA) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).